Last $4.67 USD
Change Today +0.16 / 3.55%
Volume 1.3M
IDRA On Other Exchanges
As of 4:30 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

idera pharmaceuticals inc (IDRA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/14 - $6.87
52 Week Low
10/10/14 - $1.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

idera pharmaceuticals inc (IDRA) Related Businessweek News

No Related Businessweek News Found

idera pharmaceuticals inc (IDRA) Details

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States. The company’s lead drug candidates in TLR program includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of various autoimmune diseases, such as moderate to severe plaque psoriasis, polymyositis, dermatomyositis, Waldenström’s macroglobulinemia, and diffuse large B-cell lymphoma; and IMO-9200 that is in preclinical studies that supports the submission of an investigational new drug application to the United States Food and Drug Administration. It is also involved in the initiation of research program that employs gene silencing oligonucleotides to inhibit the production of disease-associated proteins by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; license and research collaboration agreement with Merck Sharp & Dohme Corp. to develop and commercialize TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease; and an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.

18 Employees
Last Reported Date: 03/13/14
Founded in 1989

idera pharmaceuticals inc (IDRA) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $409.5K
Vice President of Clinical Development
Total Annual Compensation: $390.0K
Vice President of Development Programs & Alli...
Total Annual Compensation: $388.7K
President of Research and Director
Total Annual Compensation: $823.5K
Compensation as of Fiscal Year 2013.

idera pharmaceuticals inc (IDRA) Key Developments

Idera Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:30 AM

Idera Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Vincent J. Milano, Chief Executive Officer and Director.

Idera Pharmaceuticals, Inc. Provides Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia

Idera Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of Waldenström's macroglobulinemia (WM). Additionally, Idera is providing a progress update on the ongoing Phase 1/2 clinical trial being conducted in WM. Idera is currently conducting a Phase 1/2 clinical trial of IMO-8400 in patients with WM ( identifier NCT02092909) who have a history of relapse or failure to respond to one or more prior therapies. In B-cell lymphomas characterized by the MYD88 L265P oncogenic mutation, including WM, preclinical studies have shown that TLR signaling is overactivated, thereby enabling tumor cell survival and proliferation. About 90% of WM patients are reported to harbor the MYD88 L265P oncogenic mutation. The objectives of the trial are to evaluate the compound's safety, tolerability and potential clinical activity. The protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously. The trial's independent data review committee has completed its review of four-week safety data from the second dose cohort (1.2 mg/kg/week) and has determined that Idera may open enrollment in the third dose cohort (2.4 mg/kg/week). Final 24-week safety and clinical activity data are anticipated in the second half of 2015. Orphan drug designation is granted by the FDA Office of Orphan Products Development to drugs intended for the treatment of a rare disease or condition that affects fewer than 200,000 people in the United States. This designation provides certain incentives, including eligibility for federal grants, research and development tax credits, waiver of PDUFA filing fees and a seven-year marketing exclusivity period, once the product is approved and as long as orphan drug designation is maintained.

Idera Pharmaceuticals, Inc. Announces Key Additions to Management Team

Idera Pharmaceuticals, Inc. announced that it has appointed J. Peter Wolf as Senior Vice President, General Counsel and Elizabeth Eberhardt as Vice President, Oncology Team. Mr. Wolf most recently served as Vice President, General Counsel and Secretary of ViroPharma Incorporated from January 2008 until January 2014 and Associate General Counsel upon joining ViroPharma in 2004. Ms. Eberhardt most recently served as Senior Director of Project Management at ViroPharma Incorporated. .


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $4.67 USD +0.16

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies

Industry Analysis


Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5,082.9x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,297.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at